Delivery Order SPE2DB20D3101-SPE2DB25FRNJ2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $14,934.34 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a $4,650.48 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on July 24, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 25, 2025 and performance location in Conshohocken, Pennsylvania. The delivery order represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $4,190.16 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens (2 mL quantity) on September 11, 2025, with completion scheduled for September 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,201.02 for Dupixent 300 mg/2 ml pen injections on April 18, 2025, with an ultimate completion date of April 21, 2025. This firm fixed-price delivery order represents a non-competitive set-aside procurement and is being fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $6,117.04. This non-set-aside contract is classified as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. The work will be...
- The Defense Logistics Agency awarded a $10,809.15 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The contract carries no set-aside designation and will be...
- The Defense Logistics Agency awarded a delivery order valued at $5,389.54 to AmerisourceBergen Drug Corp for Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 6, 2025, with completion expected by August 7, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,340.32 on September 9, 2025, for the supply of Dupixent 300 mg/2 mL pens. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 10, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $8,547.30 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen (2 mL) on August 29, 2025, with an ultimate completion date of September 2, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal medical procurement vendor, particularly for military and...
- The Defense Logistics Agency awarded a delivery order valued at $13,253.95 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child action under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRNJ2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $15,170.76 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pens on June 20, 2025, with an ultimate completion date of June 23, 2025. This firm fixed-price, non-set-aside delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999 ceiling value and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical procurement vendor for military and veteran healthcare systems. The company's comprehensive IDC vehicle enables it to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally. This specific delivery order for Dupixent, a specialty pharmaceutical indicated for conditions including atopic dermatitis and eosinophilic esophagitis, reflects the company's role in providing brand-name medications and specialized healthcare commodities across multiple therapeutic domains to federal healthcare customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.2k | 6/20/25 |